Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2007

Bayer and Nektar Partner to Fight Gram-Negative Pneumonias in $175M Alliance

  • Bayer HealthCare and Nektar Therapeutics will work together to develop and commercialize an adjunctive treatment of Gram-negative pneumonias. NKTR-061 is currently in Phase II a trials. Nektar will utilize its pulmonary technology to deliver this specially formulated amikacin, an aminoglycoside antibiotic, for inhalation deep into the lung.

    As part of this agreement, Nektar will receive milestone payments of up to $175 million. This includes an upfront payment of $50 million. Subsequent to the successful clinical and regulatory development of the product, Bayer HealthCare and Nektar have agreed co-promote the product in the U.S. and to share profits. For sales outside the U.S., Nektar will receive tiered royalties up to a maximum of 30%.

    Bayer HealthCare is responsible for the global clinical development, regulatory strategy, manufacturing, and marketing of the product, with Nektar participating in all aspects of decision-making and governance.

    This collaboration is Bayer HealthCare's second with Nektar. In 2005, Bayer and Nektar agreed to collaborate on the joint development of inhaled ciprofloxacin as a potential dry powder therapy for treating pseudomonal infections in patients suffering from cystic fibrosis.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »